Published in Mol Imaging Biol on October 01, 2014
Challenges of Pancreatic Cancer. Cancer J (2015) 0.96
Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with (89)Zr-5B1. Mol Pharm (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol (1981) 14.45
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging (2003) 8.56
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging (1997) 3.65
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A (1996) 3.37
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology (1996) 2.28
Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg (2003) 2.26
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene (2000) 2.19
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol (1999) 1.61
Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer (1986) 1.45
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol (2006) 1.25
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol (2010) 1.17
Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med (2000) 1.17
Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res (2011) 1.06
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 1.04
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00
Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol (1993) 0.99
Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res (2011) 0.94
The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol (1986) 0.94
CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging (2011) 0.89
Detection of monoclonal antibody-defined colorectal carcinoma antigen by solid-phase binding inhibition radioimmunoassay. Hybridoma (1981) 0.78
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel (2006) 3.27
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat Methods (2007) 2.64
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res (2003) 2.36
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol (2008) 2.20
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg (2008) 1.90
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol (2008) 1.82
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Antibody vectors for imaging. Semin Nucl Med (2010) 1.60
Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg (2011) 1.59
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res (2005) 1.54
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg (2007) 1.44
Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci (2008) 1.44
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol (2002) 1.42
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg (2007) 1.41
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol (2005) 1.37
Solution-phase surface modification in intact poly(dimethylsiloxane) microfluidic channels. Anal Chem (2006) 1.33
Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol (2007) 1.33
Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol (2008) 1.32
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1.27
An internet-based "kinetic imaging system" (KIS) for MicroPET. Mol Imaging Biol (2006) 1.27
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel (2004) 1.25
Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res (2008) 1.23
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20
Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene (2002) 1.18
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 1.18
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel (2004) 1.18
Positive progress in immunoPET--not just a coincidence. Cancer Biother Radiopharm (2010) 1.14
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother (2007) 1.13
Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel (2008) 1.11
Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol (2010) 1.09
Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med (2008) 1.09
Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol (2002) 1.08
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res (2007) 1.08
Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res (2011) 1.06
Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg (2014) 1.06
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel (2004) 1.05
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (2003) 1.05
Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg (2008) 1.05
Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng Des Sel (2006) 1.05
Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology (2009) 1.04
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2014) 1.04
A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther (2006) 1.03
ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol (2012) 1.03
Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning. J Biol Chem (2010) 1.03
Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med (2014) 1.03
The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol (2003) 1.02
Patient satisfaction: an increasingly important measure of quality. Ann Surg Oncol (2006) 1.02
Impact of adjuvant radiation on survival: a note of caution when using cancer registry data to evaluate adjuvant treatments. Ann Surg Oncol (2007) 1.00
Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv (2006) 1.00
Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjug Chem (2008) 1.00
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00
Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomol Eng (2007) 0.99
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res (2004) 0.98
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel (2010) 0.97
Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjug Chem (2009) 0.97
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm (2006) 0.95
Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem (2006) 0.95
Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res (2011) 0.94
Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg (2007) 0.93
Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography. Mol Imaging (2011) 0.92
Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer. J Gastrointest Surg (2014) 0.91
Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm (2014) 0.91
Trends, patterns, and outcomes in the management of malignant colonic polyps in the general population of the United States. Cancer (2010) 0.91
Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res (2008) 0.90
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol (2012) 0.90
CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging (2011) 0.89
Utilization of parenteral nutrition following pancreaticoduodenectomy: is routine jejunostomy tube placement warranted? Dig Dis Sci (2008) 0.89
Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol (2013) 0.88
Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nucl Med Biol (2009) 0.87
Cystic neoplasms of the pancreas: results of 114 cases. Pancreas (2010) 0.87
Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. J Biomed Opt (2013) 0.87
Dual transcript and protein quantification in a massive single cell array. Lab Chip (2016) 0.86
Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Eng Des Sel (2010) 0.86
Rates and equilibria for probe capture by an antibody with infinite affinity. Bioconjug Chem (2010) 0.86
Unexpected readmissions after major cancer surgery: an evaluation of readmissions as a quality-of-care indicator. Surg Oncol Clin N Am (2012) 0.86
Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model. FEMS Immunol Med Microbiol (2009) 0.85
Expression of recombinant antibodies in mammalian cell lines. Methods Mol Biol (2004) 0.85
An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg Res (2013) 0.85
A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm (2010) 0.83